Latest Articles

Publication Date
All News Scientific
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat

Published: Feb. 27, 2026, 4:50 p.m.
Read Full Article
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance

Published: Feb. 27, 2026, 4:47 p.m.
Read Full Article
Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress - Investing.com

Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress Investing.com

Published: Feb. 27, 2026, 2:18 p.m.
Read Full Article
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference The Manila Times

Published: Feb. 24, 2026, 1:18 p.m.
Read Full Article
The role of probiotics in the treatment of endometriosis (ProMetrioS): a randomized double-blinded placebo-controlled cross-over trial.

ProMetrioS is a randomized, blinded, placebo-controlled cross-over trial investigating the effect of a specific multispecies probiotic in patients with endometriosis. The aim of this clinical trial is to determine whether …

Published: Feb. 20, 2026, midnight
Read Full Article
Endometriosis Estrobolome Gut microbiome Gut-microbiome therapeutics Pain Probiotics Quality of life Symptoms
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance - HIT Consultant

Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance HIT Consultant

Published: Feb. 18, 2026, 5:03 p.m.
Read Full Article
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Priva - PharmiWeb.com

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Priva PharmiWeb.com

Published: Feb. 18, 2026, 4:05 p.m.
Read Full Article
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - PharmiWeb.com

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement PharmiWeb.com

Published: Feb. 18, 2026, 4:05 p.m.
Read Full Article
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Read Full Article
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!